we are pleased to inform that, Board of Directors at their meeting held on today i.e. Wednesday 21st May, 2025 has inter alia considered and approved:- a) Audited Standalone ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, along with the auditor's unmodified opinion. Standalone revenue fell sharply from Rs 716.54 lacs to Rs 241.66 lacs (down ~66%), dragged by the Real Estate division where shop sales dropped from Rs 731.26 lacs to Rs 241.66 lacs. The Pharma segment grew from Rs 2050.73 lacs to Rs 2306.05 lacs (up ~12%). Consolidated revenue slipped ~8% to Rs 2547.71 lacs, but consolidated loss narrowed from Rs 224.03 lacs to Rs 57.10 lacs. Standalone PAT dropped from Rs 388.82 lacs to Rs 28.50 lacs (down ~93%), aided by an earlier-year tax write-back of Rs 25.56 lacs. Praveen Shrivastava & Company was re-appointed as Internal Auditor for FY26.
The steep standalone profit fall and weak Real Estate revenue are negatives, but the narrower consolidated loss, debt-free balance sheet (zero borrowings), and growing Pharma division offer some comfort. Unmodified auditor opinion is a clean signal, though prior period figures were restated/regrouped.